Puntos clave de insuficiencia cardiaca en algunas situaciones especiales
DOI:
https://doi.org/10.18041/2665-427X/ijeph.2.9883Palabras clave:
Insuficiencia cardíaca, tuberculosis diabetes mellitus, insuficiencia renal crónica, fibrilación atrial, deficiencia de hierroResumen
Introducción: La insuficiencia cardiaca (IC) es una patología de alta prevalencia en todo el mundo, su tratamiento no solo va de la mano de la patología en sí, la optimización de algunas de las enfermedades que suelen rodear esta patología impacta de manera directa sobre el curso de la enfermedad.
Metodos: Se realizó una revisión narrativa de la literatura.
Resultados: En pacientes con IC con Fracción de eyección preservada los iSGLT-2 son los únicos medicamentos que han mostrado utilidad en esta subpoblación independiente de su estado comórbido con diabetes, además en paciente con IC con fracción reducida con o sin diabetes su inicio puede realizarse de forma temprana desde el alta generando impacto en los desenlaces de MACE, hospitalización y mortalidad. En cuanto a enfermedad renal crónica los medicamentos usados en IC ya no son considerados nefrotóxicos, ya que su uso si bien produce una reducción de la Tasa de Filtración Glomerular (TFG) a largo plazo retrasan su deterioro y mejoran pronostico. Además el adecuado manejo de la deficiencia de Hierro y la fibrilación auricular disminuyen los desenlaces adversos y mejoran la calidad de vida.
Conclusiones: el manejo oportuno de la diabetes mellitus tipo 2 y la Enfermedad Renal crónica es fundamental para controlar la progresión de la insuficiencia Cardiaca, así mismo las terapéuticas como el uso de hierro carboximaltosa y el adecuado abordaje terapéutico de la fibrilación auricular son determinantes para disminuir desenlaces adversos y mejorar la calidad de vida.
Descargas
Referencias
Ciapponi A, Alcaraz A, Calderón M, Matta MG, Chaparro M, Soto N, et al. Burden of heart failure in Latin America: a systematic review and meta-analysis. Rev Esp Cardiol Engl Ed. 2016; 69: 1051-60. Doi: 10.1016/j.rec.2016.04.054.
Gómez-Mesa JE, Saldarriaga-Giraldo CI, Echeverría LE, Luna P, Recolfaca GI. Registro colombiano de falla cardiaca (RECOLFACA): metodología y datos preliminares. Rev Colomb Cardiol. 2021; 28(3):217-230. Doi: 10.24875/RCCAR.M21000021.
Chopra VK, Anker SD. Anaemia, iron deficiency and heart failure in 2020: facts and numbers. ESC Heart Fail. 2020; 7: 2007-11. Doi: 10.1002/ehf2.12797.
Becher PM, Schrage B, Benson L, Fudim M, Corovic Cabrera C, Dahlström U, et al. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2021;23:1844-54. Doi: 10.1002/ejhf.2338.
Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021;42:681-3. Doi: 10.1093/eurheartj/ehaa1012.
Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction. Circ Heart Fail. 2016;9:e002560. Doi: 10.1161/CIRCHEARTFAILURE.115.002560.
Zapatero-Gaviria A, Gómez-Huelgas R, Canora-Lebrato J, Ena-Muñoz J, Romero-Sánchez M, Mendez-Bailón M, et al. Análisis de las hospitalizaciones por enfermedad cardiovascular en población diabética en España. Rev Clínica Esp. 2019;219:124-9. Doi: 10.1016/j.rce.2018.09.012.
McMurray JJV, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2:843-51. Doi: 10.1016/S2213-8587(14)70031-2.
Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:422-34. Doi: 10.1016/j.jacc.2019.11.031.
Staplin N, Roddick AJ, Emberson J, Reith C, Riding A, Wonnacott A, et al. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine. 2021;41: 101163. Doi: 10.1016/j.eclinm.2021.101163.
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776-85. Doi: 10.1016/S2213-8587(19)30249-9.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008. Doi: 10.1056/NEJMoa1911303.
Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, et al. Prospective ARNI vs. ACE inhibitor trial to determIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021;23:1040-8. Doi: 10.1002/ejhf.2191.
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021; 384: 117-28. Doi: 10.1056/NEJMoa2030183.
Le VT, Perez-Moreno AC, Calderone P, Epstein J, Muhlestein JB, Knowlton KU, et al. Combined therapy with sodium-glucose cotransporter-2 inhibitors (sglt2i) and glucagon-like peptide-1 receptor agonists (glp1-ra)—tolerability and clinical impact: the intermountain healthcare real world experience. J Am Coll Cardiol. 2022;79:1443-1443. Doi: 10.1016/S0735-1097(22)02434-2.
Li C, Luo J, Jiang M, Wang K. The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2022;13: 838277. doi: 10.3389/fphar.2022.838277.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-61. Doi: 10.1056/NEJMoa2107038.
Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24:603-19. Doi: 10.1002/ejhf.2471.
Clark AL, Kalra PR, Petrie MC, Mark PB, Tomlinson LA, Tomson CR. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019;105:904-10. Doi: 10.1136/heartjnl-2018-314158.
Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31:1872-80. Doi: 10.1093/eurheartj/ehq158.
Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials: Intravenous iron therapy in systolic heart failure. Eur J Heart Fail. 2016;18:786-95. Doi: 10.1002/ejhf.473.
Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138:80-98. Doi: 10.1161/CIRCULATIONAHA.118.030099.
Ponikowski P, Kirwan B-A, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396:1895-904. Doi: 10.1016/S0140-6736(20)32339-4.
López-Vilella R, Lozano-Edo S, Arenas MP, Jover-Pastor P, Ezzitouny M, Sorolla Romero J, et al. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2022;9:133-45. Doi: 10.1002/ehf2.13753.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e263-421. Doi: 10.1016/j.jacc.2021.12.012.
Lardizabal JA, Deedwania PC. Atrial fibrillation in heart failure. Med Clin North Am. 2012;96:987-1000. Doi: 10.1016/j.mcna.2012.07.007.
Carlisle MA, Fudim M, Devore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail. 2019; 7(6): 447-456. doi: 10.1016/j.jchf.2019.03.005.
Verma A, Kalman JM, Callans DJ. Treatment of patients with atrial fibrillation and heart failure with reduced ejection fraction. Circulation. 2017;135:1547-63. Doi: 10.1161/CIRCULATIONAHA.116.026054.
Samet P, Bernstein W, Levine S. Significance of the atrial contribution to ventricular filling. Am J Cardiol. 1965;15:195-202. Doi: 10.1016/0002-9149(65)90454-6.
Solti F, Vecsey T, KékesI V, Juhász-Nagy A. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res. 1989;23:882-6. Doi: 10.1093/cvr/23.10.882.
Boos CJ, Anderson RA, Lip GYH. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006;27:136-49. Doi: 10.1093/eurheartj/ehi645.
Hu Y-F, Chen Y-J, Lin Y-J, Chen S-A. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12:230-43. Doi: 10.1038/nrcardio.2015.2.
Negi S, Shukrullah I, Veledar E, Bloom HL, Jones DP, Dudley SC. Statin Therapy for the Prevention of Atrial Fibrillation Trial (SToP AF trial). J Cardiovasc Electrophysiol. 2011;22:414-9. Doi: 10.1111/j.1540-8167.2010.01925.x.
Bang CN, Greve AM, Abdulla J, Køber L, Gislason GH, Wachtell K. The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: A systematic review and meta-analysis. Int J Cardiol. 2013;167:624-30. Doi: 10.1016/j.ijcard.2012.08.056.
Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 2017;5:565-74. Doi: 10.1016/j.jchf.2017.05.001.
Brown LAE, Boos CJ. Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant. Int J Cardiol. 2017;227:863-8. Doi: 10.1016/j.ijcard.2016.09.086.
Sandhu RK, Hohnloser SH, Pfeffer MA, Yuan F, Hart RG, Yusuf S, et al. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. Stroke. 2015;46:667-72. Doi: 10.1161/STROKEAHA.114.007140.
Kotecha D, Banerjee A, Lip GYH. Increased stroke risk in atrial fibrillation patients with heart failure. Stroke. 2015;46:608-9. Doi: 10.1161/STROKEAHA.114.008421.
Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. N Engl J Med 2008;358:2667-77. Doi: 10.1056/NEJMoa0708789.
Camm AJ, Naccarelli GV, Mittal S, Crijns HJGM, Hohnloser SH, Ma C-S, et al. The increasing role of rhythm control in patients with atrial fibrillation: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79:1932-48. Doi: 10.1016/j.jacc.2022.03.337.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498. Doi: 10.1093/eurheartj/ehaa612.
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417-27. Doi: 10.1056/NEJMoa1707855.
Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013;61:1894-903. Doi: 10.1016/j.jacc.2013.01.069.
Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014;7:31-8. Doi: 10.1161/CIRCEP.113.000806.
Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device. Circulation. 2016;133:1637-44. Doi: 10.1161/CIRCULATIONAHA.115.019406.
Descargas
Publicado
Versiones
- 2023-03-15 (2)
- 2022-12-30 (1)
Número
Sección
Licencia
Derechos de autor 2022 Interdisciplinary Journal of Epidemiology and Public Health
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
